Join to view full profile
43 New Scotland Ave# MC-13Albany, NY 12208
Phone+1 518-262-6696
Fax+1 518-373-3931
Dr. Zackon is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1992 - 1994
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1990 - 1992
McGill University Faculty Medicine HospitalInternal Medicine, 1986 - 1989
McGill University Faculty of MedicineClass of 1986
Certifications & Licensure
GA State Medical License 2025 - 2027
NY State Medical License 1997 - 2026
IL State Medical License 1992 - 1996
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed™ EHR, US Oncology, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
Clinical Trials
- Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 Feb 01
- Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation Start of enrollment: 2018 Jan 01
Publications & Presentations
PubMed
- 6 citationsShared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.Gregory A Abel, Haesook T Kim, Ira Zackon, Edwin T Alyea, Alexandra S Bailey
JAMA Oncology. 2025-03-01 - 4 citationsCharacteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices.Roger M Lyons, Kathleen M Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum
Current Medical Research and Opinion. 2025-01-01 - Nonspecific Signs and/or Symptoms of Cancer: A Retrospective, Observational Analysis from a Secondary Care, US Community Oncology Dataset.Christopher B Benton, Ding He, Karen Todoroff, Marie V Coignet, Ying Luan
Current Oncology. 2024-06-25
Journal Articles
- A Phase 1/2 Study of Evofosfamide, A Hypoxia-Activated Prodrug with or Without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaNoopur S Raje, Ira Zackon, Clinical Cancer Research
Press Mentions
Bispecific Use for Myeloma Spikes in Community OncologyDecember 10th, 2025- Community Oncology Practices Can Overcome Hurdles in Providing Bispecifics for Multiple MyelomaApril 28th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
